deltatrials
Completed PHASE3 NCT00095394

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension

Sponsor: Bristol-Myers Squibb

Conditions Hypertension
Interventions Irbesartan monotherapy Irbesartan/HCTZ
Updated 8 times since 2017 Last updated: Apr 7, 2011 Started: Sep 30, 2004 Primary completion: May 31, 2005 Completion: May 31, 2005

This PHASE3 trial investigates Hypertension and is currently completed. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Sanofi
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Ambrières-les-Vallées, France, Angers, France, Antwerp, Belgium, Atlanta, United States, Austin, United States, Ayer, United States, Aylmer, Canada, Bagneux, France, Baltimore, United States and 258 more location s